Thrombin Generation Assays in Clinical Hemostasis: From Mechanistic Insights to Clinical Applications

Abstract

Thrombin plays a central role in hemostasis, serving as both the primary enzyme driving fibrin formation and the central regulator of anticoagulant pathways. Routine coagulation assays, such as prothrombin time and activated partial thromboplastin time, capture only a limited fraction of thrombin's role, overlooking inhibitory pathways and downstream regulation. Thrombin generation assays (TGAs) provide a global view of coagulation, measuring both formation and inhibition of thrombin over time. TGAs generate thrombin activity curves, from which parameters such as lag time, peak thrombin, time to peak, velocity index, and endogenous thrombin potential are derived. These parameters reflect hyper- or hypocoagulability and have been linked to clinical outcomes. Applications include monitoring anticoagulant therapy and reversal strategies, predicting venous thromboembolism recurrence, assessing thrombotic risk in cardiovascular disease and antiphospholipid syndrome, and stratifying bleeding risk in bleeding disorders. TGAs can also evaluate the efficacy of bypassing agents and novel hemostatic drugs in ex vivo settings. Barriers include technical complexity, preanalytical variability, and lack of standardization across laboratories. TGAs provide a global assessment of coagulation, demonstrating added value in both hyper- and hypocoagulable states. While most data remain research-based, growing evidence supports their utility in thrombotic risk prediction and bleeding risk assessment. Wider adoption in clinical practice will depend on assay standardization, validation in multicenter studies, and integration into clinical decision-making pathways.

Keywords

thrombin generation - coagulation - thrombosis - bleeding risk - global coagulation assays - laboratory hemostasis diagnostics - thrombophilia

Authors' Contributions

J.G.: conceptualization, data curation, investigation, methodology, project administration, writing–original draft, writing–review and editing. C.V.L.: conceptualization, methodology, supervision, writing–review and editing.

Publikationsverlauf

Eingereicht: 04. Oktober 2025

Angenommen nach Revision: 10. Februar 2026

Accepted Manuscript online:
13. Februar 2026

Artikel online veröffentlicht:
26. Februar 2026

• References

• 1 Gale AJ. Continuing education course #2: Current understanding of hemostasis. Toxicol Pathol 2011; 39 (01) 273-280
• 2 Sidonio Jr RF, Hoffman M, Kenet G, Dargaud Y. Thrombin generation and implications for hemophilia therapies: A narrative review. Res Pract Thromb Haemost 2022; 7 (01) 100018
• 3 Mann KG, Brummel K, Butenas S. What is all that thrombin for?. J Thromb Haemost 2003; 1 (07) 1504-1514
• 4 Hemker HC, Wielders S, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70 (04) 617-624
• 5 Wu Y, Lu Y, Zhang J. Thrombin generation assay: The present and the future. Blood Coagul Fibrinolysis 2023; 34 (01) 1-7
• 6 Depasse F, Binder NB, Mueller J. et al. Thrombin generation assays are versatile tools in blood coagulation analysis: A review of technical features, and applications from research to laboratory routine. J Thromb Haemost 2021; 19 (12) 2907-2917
• 7 Wan J, Konings J, de Laat B, Hackeng TM, Roest M. Added value of blood cells in thrombin generation testing. Thromb Haemost 2021; 121 (12) 1574-1587
• 8 Tripodi A. Thrombin generation assay and its application in the clinical laboratory. Clin Chem 2016; 62 (05) 699-707
• 9 Tripodi A, Chantarangkul V, Mannucci PM. Acquired coagulation disorders: revisited using global coagulation/anticoagulation testing. Br J Haematol 2009; 147 (01) 77-82
• 10 Shirts BH, Rodgers GM, Smock KJ. Prothrombin time, activated partial thromboplastin time and dilute Russell's Viper Venom times are not shorter in patients with the prothrombin G20210A mutation, and dilute Russell's Viper Venom time may be longer. Thromb Res 2012; 130 (03) e134-e138
• 11 Binder NB, Depasse F, Mueller J. et al. Clinical use of thrombin generation assays. J Thromb Haemost 2021; 19 (12) 2918-2929
• 12 Chen A, Stecker E, A. Warden B. Direct oral anticoagulant use: A practical guide to common clinical challenges. J Am Heart Assoc 2020; 9 (13) e017559
• 13 Artang R, Anderson M, Riley P, Nielsen JD. Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay. Res Pract Thromb Haemost 2017; 1 (02) 194-201
• 14 Kyriakou E, Katogiannis K, Ikonomidis I. et al. Laboratory assessment of the anticoagulant activity of apixaban in patients with nonvalvular atrial fibrillation. Clin Appl Thromb Hemost 2018; 24 (9_suppl): 194S-201S
• 15 Herrmann R, Thom J, Wood A, Phillips M, Muhammad S, Baker R. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban. Thromb Haemost 2014; 111 (05) 989-995
• 16 Meihandoest T, Studt JD, Mendez A. et al. Automated thrombin generation assay for rivaroxaban, apixaban, and edoxaban measurements. Front Cardiovasc Med 2021; 8: 717939
• 17 Schultz NH, Tran HTT, Bjørnsen S, Henriksson CE, Sandset PM, Holme PA. The reversal effect of prothrombin complex concentrate (PCC), activated PCC and recombinant activated factor VII against anticoagulation of Xa inhibitor. Thromb J 2017; 15: 6
• 18 Siegal DM, Curnutte JT, Connolly SJ. et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373 (25) 2413-2424
• 19 Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124 (14) 1573-1579
• 20 Schenk B, Würtinger P, Streif W, Sturm W, Fries D, Bachler M. Ex vivo reversal of effects of rivaroxaban evaluated using thromboelastometry and thrombin generation assay. Br J Anaesth 2016; 117 (05) 583-591
• 21 Brinkman HJM, Swieringa F, Zuurveld M. et al. Reversing direct factor Xa or thrombin inhibitors: Factor V addition to prothrombin complex concentrate is beneficial in vitro. Res Pract Thromb Haemost 2022; 6 (03) e12699
• 22 Song Y, Wang Z, Perlstein I. et al. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: A randomized three-period crossover study. J Thromb Haemost 2017; 15 (11) 2125-2137
• 23 Kaatz S, Bhansali H, Gibbs J, Lavender R, Mahan CE, Paje DG. Reversing factor Xa inhibitors - clinical utility of andexanet alfa. J Blood Med 2017; 8: 141-149
• 24 Balandina AN, Serebriyskiy II, Poletaev AV. et al. Thrombodynamics-A new global hemostasis assay for heparin monitoring in patients under the anticoagulant treatment. PLoS ONE 2018; 13 (06) e0199900
• 25 Samama MM, Kunitada S, Oursin A, Depasse F, Heptinstall S. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adults. Thromb Res 2010; 126 (04) e286-e293
• 26 Samama MM, Le Flem L, Guinet C, Gerotziafas G, Depasse F. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost 2007; 5 (12) 2554-2556
• 27 Zwaveling S, Bloemen S, de Laat B, Ten Cate H, Ten Cate-Hoek A. Calibrated automated thrombinography (CAT), a tool to identify patients at risk of bleeding during anticoagulant therapy: A systematic review. TH Open 2018; 2 (03) e291
• 28 de Breet CPDM, Zwaveling S, Vries MJA. et al. Thrombin generation as a method to identify the risk of bleeding in high clinical-risk patients using dual antiplatelet therapy. Front Cardiovasc Med 2021; 8: 679934
• 29 Gerotziafas GT, Depasse F, Chakroun T, Samama MM, Elalamy I. Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost 2004; 91 (03) 531-537
• 30 Spiezia L, Rossetto V, Campello E, Bulato C, Radu CM, Simioni P. Thrombin generation and thromboelastometry in monitoring the in-vitro reversal of warfarin: A comparison between 3-factor and 4-factor prothrombin complex concentrates. Blood Coagul Fibrinolysis 2020; 31 (02) 127-131
• 31 Efimenko E, Zhao H, Moskowitz K, Smith C, Pyo R, Diacovo TG. Preclinical efficacy of a hemostatic agent in overcoming dual antiplatelet therapy. JACC Basic Transl Sci 2025; 10 (09) 101356
• 32 Bezemer ID, Bare LA, Doggen CJ. et al. Gene variants associated with deep vein thrombosis. JAMA 2008; 299 (11) 1306-1314
• 33 Souto JC, Almasy L, Borrell M. et al. Genetic susceptibility to thrombosis and its relationship to physiological risk factors: The GAIT study. Genetic analysis of idiopathic thrombophilia. Am J Hum Genet 2000; 67 (06) 1452-1459
• 34 Pastori D, Cormaci VM, Marucci S. et al. A comprehensive review of risk factors for venous thromboembolism: From epidemiology to pathophysiology. Int J Mol Sci 2023; 24 (04) 3169
• 35 Hron G, Kollars M, Binder BR, Eichinger S, Kyrle PA. Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation. JAMA 2006; 296 (04) 397-402
• 36 Ay C, Dunkler D, Simanek R. et al. Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2011; 29 (15) 2099-2103
• 37 Castoldi E, Simioni P, Tormene D. et al. Differential effects of high prothrombin levels on thrombin generation depending on the cause of the hyperprothrombinemia. J Thromb Haemost 2007; 5 (05) 971-979
• 38 Gyldenholm T, Hvas AM, Christensen TD, Larsen JB. Thrombin generation markers as predictors of cancer-associated venous thromboembolism: A systematic review. Semin Thromb Hemost 2024; 50 (03) 384-401
• 39 Souza MEM, Ferreira LGR, Silva NRO, Lopes LR, das Graças Carvalho M, Rios DRA. Thrombin generation assay in venous thromboembolism: A scoping review. Thromb Res 2025; 252: 109384
• 40 Caspary L, Shaw JR, Stalder O, Brodard J, Angelillo-Scherrer A, Vrotniakaite-Bajerciene K. Clinical utility of thrombin generation using ST-Genesia® in patients with hereditary and acquired thrombophilia: A cross-sectional study. Thromb Res 2025; 254: 109454
• 41 Ramanan R, Verstraete A, Van Laer C, Freson K. Implementation and clinical utility of multigene panels for bleeding, platelet, and thrombotic disorders. J Thromb Haemost 2025; 23 (08) 2371-2387
• 42 Van Laer C, Jacquemin M, Baert S. et al. Clinical application of multigene panel testing for bleeding, thrombotic, and platelet disorders: A 3-year Belgian experience. J Thromb Haemost 2023; 21 (04) 887-895
• 43 Van Laer C, Lavend'homme R, Baert S. et al. Functional assessment of genetic variants in thrombomodulin detected in patients with bleeding and thrombosis. Blood 2025; 145 (17) 1929-1942
• 44 Van Laer C, Vanrenterghem M, Jacquemin M. et al. Genotype vs laboratory phenotype correlation of defects in natural anticoagulants in patients with venous thromboembolism. J Thromb Haemost 2025; 23 (09) 2873-2882
• 45 Hézard N, Bouaziz-Borgi L, Remy MG, Nguyen P. Utility of thrombin-generation assay in the screening of factor V G1691A (Leiden) and prothrombin G20210A mutations and protein S deficiency. Clin Chem 2006; 52 (04) 665-670
• 46 Foret T, Dufrost V, Lagrange J. et al. Thrombin generation assay in antiphospholipid antibodies positive subjects as a personalized thrombotic risk assessment: State of the art and perspectives. Curr Rheumatol Rep 2024; 26 (05) 178-187
• 47 Regnault V, Béguin S, Wahl D, de Maistre E, Coenraad Hemker H, Lecompte T. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003; 89 (02) 208-212
• 48 Devreese K, Peerlinck K, Arnout J, Hoylaerts MF. Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography. Thromb Haemost 2009; 101 (01) 185-196
• 49 Bradáčová P, Slavík L, Úlehlová J. et al. Determining thrombogenicity: Using a modified thrombin generation assay to detect the level of thrombotic event risk in lupus anticoagulant-positive patients. Biomedicines 2023; 11 (12) 3329
• 50 Yelnik C, Bauters A, Labreuche J. et al. Thrombin generation test as a useful tool for improving disease severity stratification in antiphospholipid syndrome. RMD Open 2025; 11 (03) e005489
• 51 de Laat-Kremers RMW, Wahl D, Zuily S. et al. A thrombin-driven neural net diagnoses the antiphospholipid syndrome without the need for interruption of anticoagulation. Blood Adv 2024; 8 (04) 936-946
• 52 Kremers RMW, Zuily S, Kelchtermans H. et al. Prothrombin conversion is accelerated in the antiphospholipid syndrome and insensitive to thrombomodulin. Blood Adv 2018; 2 (11) 1315-1324
• 53 Attanasio M, Marcucci R, Gori AM. et al. Residual thrombin potential predicts cardiovascular death in acute coronary syndrome patients undergoing percutaneous coronary intervention. Thromb Res 2016; 147: 52-57
• 54 Loeffen R, Godschalk TC, van Oerle R. et al. The hypercoagulable profile of patients with stent thrombosis. Heart 2015; 101 (14) 1126-1132
• 55 Yip C, Seneviratna A, Tan SH. et al. Patients with acute and chronic coronary syndromes have elevated long-term thrombin generation. J Thromb Thrombolysis 2020; 50 (02) 421-429
• 56 Orbe J, Zudaire M, Serrano R. et al. Increased thrombin generation after acute versus chronic coronary disease as assessed by the thrombin generation test. Thromb Haemost 2008; 99 (02) 382-387
• 57 Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96 (05) 553-561
• 58 Valke LLFG, Bukkems LH, Barteling W. et al. Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation. J Thromb Haemost 2020; 18 (12) 3222-3231
• 59 Santagostino E, Mancuso ME, Tripodi A. et al. Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile. J Thromb Haemost 2010; 8 (04) 737-743
• 60 Tarandovskiy ID, Balandina AN, Kopylov KG. et al. Investigation of the phenotype heterogeneity in severe hemophilia A using thromboelastography, thrombin generation, and thrombodynamics. Thromb Res 2013; 131 (06) e274-e280
• 61 Dargaud Y, Lienhart A, Negrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010; 116 (25) 5734-5737
• 62 Chen P, Jani J, Streiff MB, Zheng G, Kickler TS. Evaluation of global hemostatic assays in response to factor VIII inhibitors. Clin Appl Thromb Hemost 2019; 25: 1076029619836171
• 63 Negrier C, Shima M, Hoffman M. The central role of thrombin in bleeding disorders. Blood Rev 2019; 38: 100582
• 64 Pipe SW, Lissitchkov T, Georgiev P. et al. Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B. Blood Adv 2025; 9 (05) 1147-1158
• 65 Mahlangu J. Marstacimab for the treatment of hemophilia A or B. Biologics 2025; 19: 379-386
• 66 Chowdary P, Angchaisuksiri P, Apte S. et al. Concizumab prophylaxis in people with haemophilia A or haemophilia B without inhibitors (explorer8): A prospective, multicentre, open-label, randomised, phase 3a trial. Lancet Haematol 2024; 11 (12) e891-e904
• 67 Rugeri L, Beguin S, Hemker C. et al. Thrombin-generating capacity in patients with von Willebrand's disease. Haematologica 2007; 92 (12) 1639-1646
• 68 Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Negrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica 2018; 103 (04) e181-e183
• 69 Kizilocak H, Yukhtman CL, Marquez-Casas E, Lee J, Donkin J, Young G. Management of perioperative hemostasis in a severe hemophilia A patient with inhibitors on emicizumab using global hemostasis assays. Ther Adv Hematol 2019; 10: 2040620719860025
• 70 Bosch Y, Al Dieri R, ten Cate H. et al. Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: A research article. J Cardiothorac Surg 2013; 8: 154
• 71 Coakley M, Hall JE, Evans C. et al. Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding. J Thromb Haemost 2011; 9 (02) 282-292
• 72 Bartoszko J, Li H, Fitzgerald J. et al. The association of thrombin generation with bleeding outcomes in cardiac surgery: A prospective observational study. Can J Anaesth 2022; 69 (03) 311-322
• 73 Jeong D, Kim SY, Gu JY, Kim HK. Assessment of rotational thromboelastometry and thrombin generation assay to identify risk of high blood loss and re-operation after cardiac surgery. Clin Appl Thromb Hemost 2022; 28: 10 760296221123310
• 74 Bosch YP, Al Dieri R, ten Cate H. et al. Measurement of thrombin generation intra-operatively and its association with bleeding tendency after cardiac surgery. Thromb Res 2014; 133 (03) 488-494
• 75 Chandler WL. Coagulation activation during extracorporeal membrane oxygenation (ECMO). Thromb Res 2022; 211: 154-160
• 76 Schlagenhauf A, Haidl H, Trummer G. et al. The endogenous thrombin potential in patients with left ventricular assist device or heart transplant. Front Med (Lausanne) 2023; 10: 1155496
• 77 Shaw JR, Li N, Grussé M. et al. Influence of direct oral anticoagulant levels and thrombin generation on postoperative bleeding [SONAR]: A nested case-control study. Thromb Haemost 2025; 125 (12) 1226-1239
• 78 Loeffen R, Kleinegris MC, Loubele ST. et al. Preanalytic variables of thrombin generation: towards a standard procedure and validation of the method. J Thromb Haemost 2012; 10 (12) 2544-2554
• 79 Dargaud Y, Wolberg AS, Gray E, Negrier C, Hemker HC. Subcommittee on Factor VIII, Factor IX, and Rare Coagulation Disorders. Proposal for standardized preanalytical and analytical conditions for measuring thrombin generation in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost 2017; 15 (08) 1704-1707
• 80 Ninivaggi M, de Laat-Kremers R, Tripodi A. et al. Recommendations for the measurement of thrombin generation: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost 2021; 19 (05) 1372-1378
• 81 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (01) 4-15
• 82 Haisma B, Schols SEM, van Oerle RGM. et al. Comparative analysis of thrombin generation platforms for patients with coagulation factor deficiencies: A comprehensive assessment. Thromb Res 2024; 240: 109045
• 83 Kintigh J, Monagle P, Ignjatovic V. A review of commercially available thrombin generation assays. Res Pract Thromb Haemost 2017; 2 (01) 42-48
• 84 Gribkova IV, Galstyan GM, Polyanskaya TY, Sinauridze EI. Kaolin, used to trigger coagulation in thrombin generation test, increases sensitivity of the method in hemophilia patients. Blood Coagul Fibrinolysis 2020; 31 (03) 193-197
• 85 Konrath S, Mailer RK, Beerens M. et al. Intrinsic coagulation pathway-mediated thrombin generation in mouse whole blood. Front Cardiovasc Med 2022; 9: 1008410
• 86 Shaw JR, Castellucci LA, Siegal D, Carrier M. DOAC-associated bleeding, hemostatic strategies, and thrombin generation assays - a review of the literature. J Thromb Haemost 2023; 21 (03) 433-452
• 87 Honoré ML, Pihl TH, Nielsen LN. A pilot study evaluating the Calibrated Automated Thrombogram assay and application of plasma-thromboelastography for detection of hemostatic aberrations in horses with gastrointestinal disease. BMC Vet Res 2021; 17 (01) 346
• 88 Arachchillage DRJ, Efthymiou M, Mackie IJ, Lawrie AS, Machin SJ, Cohen H. Rivaroxaban and warfarin achieve effective anticoagulation, as assessed by inhibition of TG and in-vivo markers of coagulation activation, in patients with venous thromboembolism. Thromb Res 2015; 135 (02) 388-393
• 89 Morimont L, Haguet H, Dogné JM, Gaspard U, Douxfils J. Combined oral contraceptives and venous thromboembolism: Review and perspective to mitigate the risk. Front Endocrinol (Lausanne) 2021; 12: 769187
• 90 Haidl H, Cimenti C, Leschnik B, Zach D, Muntean W. Age-dependency of thrombin generation measured by means of calibrated automated thrombography (CAT). Thromb Haemost 2006; 95 (05) 772-775
• 91 de Laat-Kremers RMW, Ninivaggi M, Devreese KMJ, de Laat B. Towards standardization of thrombin generation assays: Inventory of thrombin generation methods based on results of an International Society of Thrombosis and Haemostasis Scientific Standardization Committee survey. J Thromb Haemost 2020; 18 (08) 1893-1899
• 92 Ninivaggi M, de Laat-Kremers RMW, Carlo A, de Laat B. ST Genesia reference values of 117 healthy donors measured with STG-BleedScreen, STG-DrugScreen and STG-ThromboScreen reagents. Res Pract Thromb Haemost 2020; 5 (01) 187-196
• 93 Kristensen SR, Nybo J, Pedersen S. Thrombin generation measured on ST Genesia, a new platform in the coagulation routine lab: Assessment of analytical and between-subject variation. Res Pract Thromb Haemost 2022; 6 (01) e12654
• 94 van Hylckama Vlieg A, Christiansen SC, Luddington R, Cannegieter SC, Rosendaal FR, Baglin TP. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence. Br J Haematol 2007; 138 (06) 769-774
• 95 van Hylckama Vlieg A, Baglin CA, Luddington R, MacDonald S, Rosendaal FR, Baglin TP. The risk of a first and a recurrent venous thrombosis associated with an elevated D-dimer level and an elevated thrombin potential: Results of the THE-VTE study. J Thromb Haemost 2015; 13 (09) 1642-1652